Throughout these preclinical investigations, the PAH standard-of-care drugs Sildenafil, a cGMP-specific phosphodiesterase type 5 (PDE5) inhibitor, and Selexipag, an oral prostacyclin receptor agonist, were used as reference controls. Here, PDE5A is linked to pulmonary arterial hypertension.